Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspecs Group Regulatory News (SPEC)

Share Price Information for Inspecs Group (SPEC)

Share Price is delayed by 15 minutes
Get Live Data
84.50    0.00 (0.00%)
Bid:
82.00
Ask:
87.00
Spread: 5.00 (6.098%)
Market Cap: £85.91m
SPEC Live PriceLast checked at - London Stock Exchange

Intraday Inspecs Group Share Chart

Full Year Trading Update

26 Jan 2023 07:00

RNS Number : 8768N
Inspecs Group PLC
26 January 2023
Β 

26 January 2023

Inspecs Group plc

("Inspecs" or "the Group")

Β 

Full Year Trading Update

Β 

Inspecs Group plc, a leading designer, manufacturer, and distributor of eyewear (sunglasses, optical frames, lenses and low vision products), today announces a trading update for the year ended 31 December 2022 ahead of reporting its final results on 27 April 2023.

Β 

Highlights

Β· Full year trading in line with revised expectations

Β· China production volume increased in 2022 despite COVID-19 restrictions

Β· Norville losses narrowed in Q4 and further progress continues to be made

Β· Skunk Works generated its first commercial income

Β· Operational efficiencies expected to deliver further benefits in 2023

Β 

The Group's trading performance for the year, despite COVID-19 restrictions mainly in China and Vietnam, was in line with expectations as revised in October 2022, delivering Group revenue of $246.0m (2021: $246.5m). A breakdown of this revenue performance is shown below:

Β 

Revenue ($m)

12 months to 31 December 2021

Β 

12 months to 31 December 2022

Β 

Movement

Existing business

246.3

233.4

(12.9)

Acquisitions during 2021

0.2

12.6

12.4

Total

246.5

246.0

(0.5)

Β 

On a constant exchange rate basis1:

Revenue ($m)

12 months to 31 December 2021

Β 

12 months to 31 December 2022

Β 

Movement

Existing business

246.3

256.9

10.6

Acquisitions during 2021

0.2

13.1

12.9

Total

246.5

270.0

23.5

Β 

1. Constant exchange rates: figures at constant exchange rates have been calculated using the average exchange rates in effect for the corresponding period in the relevant comparative year.

Β 

On a constant exchange rate basis1, revenue increased by $23.5m from $246.5m to $270.0m, an increase of 9.5%. In Asia, our factories maintained production throughout most of the year, despite both supply chain and COVID-19 restrictions.

Β 

The Group saw a decrease in order flow in Q3 2022 following a slowdown in our German, French and other European markets, resulting in a reduction of sales in Q4. As a result, the Board implemented a cost reduction programme to improve operational efficiency in 2023. The Group's other markets remain in line with management expectations. The Group order book as at 31 December 2022 was $41.9m (31 December 2021: $42.0m on a constant currency basis).

Β 

The Group experienced several headwinds in 2022, in particular, a large decrease in the Euro against the US Dollar which had a material impact on the reporting of our European business. Freight costs, which are now reducing, were at record highs in 2022, and material, product and operating costs all rose significantly in the year. Management are making good progress at Norville, having cut costs to streamline the business and are now focused on growing revenue. Our research and development department, Skunk Works, generated its first commercial revenues in 2022 and management expect further growth in 2023.

Β 

Financial position

The Group's net debt (excluding leases) increased by $1.4m during the year to $34.1m (31 December 2021: $32.7m). Following the Group's trading update in October 2022, the Group agreed with its lender, HSBC, to a covenant waiver at 31 December 2022 and a relaxation of covenants through to 30 September 2023 to provide additional headroom. As a result, the Board will not be proposing a final dividend for 2022 or a dividend for 2023.

Β 

Outlook

The Group will continue to seek operational efficiencies and reduce costs where appropriate while maintaining execution of its growth strategy. The Group anticipates beginning construction of its new manufacturing facilities in H2 2023 funded from free cashflow. The Group enters 2023 with a good order book and is confident that it will enhance value for all stakeholders.

Β 

Richard Peck, Chief Executive Officer commented: "The Group experienced significant financial and trading headwinds in 2022 and the Board has implemented both cost reduction and operational efficiency programmes to ensure a better performance is delivered in 2023. Having taken over as CEO on 1 December 2022, I am confident that these programmes will ensure the Group is fit for the future and best placed to take advantage of the exciting growth opportunities that I see in the market."

Β 

Β 

For further information please contact:

Β 

Inspecs Group plc

Richard Peck (CEO)

Chris Kay (CFO)

Β 

via FTI Consulting

Tel: +44 (0) 20 3727 1000

Peel Hunt (Nominated Adviser and Broker)

Adrian Trimmings

Andrew Clark

Lalit Bose

Β 

Β 

Tel: +44 (0) 20 7418 8900

FTI Consulting (Financial PR)

Alex Beagley

Harriet Jackson

Alice Newlyn

Β 

Tel: +44 (0) 20 3727 1000

About Inspecs Group plc

Β 

INSPECS is a Bath-based designer, manufacturer and distributor of eyewear frames and optically advanced spectacle lenses. The Group produces a broad range of frames and lenses, covering optical, sunglasses and safety, which are either "Branded" (either under licence or under the Group's own proprietary brands), or "OEM" (including private label on behalf of retail customers, as well as unbranded).

INSPECS aims to be the leader in eyewear solutions through its vertically-integrated business model and has adopted a three-pillar growth strategy to achieve this: (i) continue to grow organically; (ii) undertake further acquisitions (and drive value through leveraging the Group's internal capabilities); and (iii) extend the Group's manufacturing capacity.

INSPECS customers include global optical and non-optical retailers, global distributors and independent opticians, with its distribution network covering over 80 countries and reaching approximately 75,000 points of sale.

INSPECS has operations across the globe: with offices and subsidiaries in the UK, Germany, Portugal, Scandinavia, the US and China (including Hong Kong, Macau and Shenzhen), and manufacturing facilities in Vietnam, China, the UK and Italy.

More information is available at: https://inspecs.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTUVONROOUAUAR
Date   Source Headline
19th May 20269:14 amRNSHolding(s) in Company
19th May 20267:00 amRNSBoard Changes
18th May 20267:00 amRNSBoard Changes
18th May 20267:00 amRNSOffer Closed
13th May 20267:00 amRNSFinal Results for the year ended 31 December 2025
1st May 20265:00 pmRNSClosure of the Offer
24th Mar 20267:00 amRNSAcceptance Level Update
18th Mar 202611:42 amRNSHolding(s) in Company
17th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
17th Mar 20269:16 amRNSForm 8.3 - INSPECS GROUP PLC
17th Mar 20267:45 amRNSDisclosure Table
17th Mar 20267:45 amRNSDisclosure Table
17th Mar 20267:00 amRNSDay 21 Acceptance Level Update
17th Mar 20267:00 amRNSDay 21 Acceptance Level Update
16th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
16th Mar 20268:44 amRNSForm 8.3 - INSPECS GROUP PLC
13th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
13th Mar 20267:00 amRNSOffer Declared Unconditional
13th Mar 20267:00 amRNSOffer Declared Unconditional
11th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
10th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
10th Mar 202610:40 amRNSHolding(s) in Company
10th Mar 20268:54 amRNSForm 8.3 - INSPECS GROUP PLC
9th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
9th Mar 20269:17 amRNSForm 8.3 - INSPECS GROUP PLC
6th Mar 20261:02 pmRNSForm 8.3 - Inspecs Group Plc
6th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
6th Mar 20269:26 amRNSForm 8.3 - INSPECS GROUP PLC
5th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
5th Mar 20269:32 amRNSForm 8.3 - INSPECS GROUP PLC
4th Mar 20265:00 pmRNSSatisfaction of NSIA Condition
4th Mar 20261:20 pmRNSAIM Rules Confirmation
4th Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
4th Mar 20269:30 amRNSForm 8.3 - INSPECS GROUP PLC
4th Mar 20268:34 amBUSForm 8.3 - Inspecs Group Plc
3rd Mar 20265:22 pmRNSHolding(s) in Company
3rd Mar 20264:38 pmRNSForm 8.3 - Inspecs Group PLC
3rd Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
2nd Mar 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
27th Feb 20261:09 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
26th Feb 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
25th Feb 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
25th Feb 20269:10 amGNWForm 8.3 - Inspecs Group Plc
23rd Feb 202612:00 pmRNSForm 8.5 (EPT/RI) Inspecs Group PLC
23rd Feb 202611:46 amRNSHolding(s) in Company
23rd Feb 202611:30 amRNSPublication of the Offer Document
20th Feb 20266:32 pmRNSSwitch to a Takeover Offer
20th Feb 20266:01 pmRNSSwitch to a Takover Offer
20th Feb 20264:30 pmRNSForm 8.3 - INSPECS GROUP PLC
20th Feb 20264:01 pmBUSForm 8.3

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.